World Journal of *Gastrointestinal Oncology*

Monthly Volume 17 Number 4 April 15, 2025





Published by Baishideng Publishing Group Inc

World Journal of Gastrointestinal

Monthly Volume 17 Number 4 April 15, 2025

EDITORIAL

Ren MJ, Zhang ZL, Tian C, Liu GQ, Zhang CS, Yu HB, Xin Q. Importance of early detection in multiple endocrine neoplasia type 1: Clinical insights and future directions. World J Gastrointest Oncol 2025; 17(4): 100013 [DOI: 10. 4251/wjgo.v17.i4.100013]

Kishikawa H, Nishida J. Gastric cancer in patients with Helicobacter pylori-negative autoimmune gastritis. World J Gastrointest Oncol 2025; 17(4): 101661 [DOI: 10.4251/wjgo.v17.i4.101661]

Tawheed A, Ismail A, El-Kassas M, El-Fouly A, Madkour A. Endoscopic resection of gastrointestinal tumors: Training levels and professional roles explored. World J Gastrointest Oncol 2025; 17(4): 101832 [DOI: 10.4251/wjgo. v17.i4.101832

Ye XX, Qu HH, Yang C, Teng WJ, Chen YP, Lin JM, Wang XB. Precision medicine in the prediction of metachronous liver metastasis in rectal cancer: Applications and challenges. World J Gastrointest Oncol 2025; 17(4): 102469 [DOI: 10.4251/wjgo.v17.i4.102469]

Sun YF, Cao XK, Wei Q, Gao YH. Potential biomarkers for the prognosis of gastrointestinal stromal tumors. World [Gastrointest Oncol 2025; 17(4): 102831 [DOI: 10.4251/wjgo.v17.i4.102831]

Lamprecht CB, Kashuv T, Lucke-Wold B. Understanding metastatic patterns in gastric cancer: Insights from lymph node distribution and pathology. World J Gastrointest Oncol 2025; 17(4): 103709 [DOI: 10.4251/wjgo.v17.i4. 103709

REVIEW

Zhang Y, Yue NN, Chen LY, Tian CM, Yao J, Wang LS, Liang YJ, Wei DR, Ma HL, Li DF. Exosomal biomarkers: A novel frontier in the diagnosis of gastrointestinal cancers. World J Gastrointest Oncol 2025; 17(4): 103591 [DOI: 10. 4251/wjgo.v17.i4.103591]

ORIGINAL ARTICLE

Case Control Study

Liu X, Zhang S, Qiu H, Xie ZQ, Tang WF, Chen Y, Wei X. Investigation of high-mobility group box 1 variants with lymph node status and colorectal cancer risk. World J Gastrointest Oncol 2025; 17(4): 102584 [DOI: 10.4251/ wjgo.v17.i4.102584]

Retrospective Cohort Study

Zhao CH, Liu H, Pan T, Xiang ZW, Mu LW, Luo JY, Zhou CR, Li MA, Liu MM, Yan HZ, Huang MS. Idarubicintransarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma. World J Gastrointest Oncol 2025; 17(4): 103776 [DOI: 10.4251/wjgo.v17.i4.103776]

Dolu S, Cengiz MB, Döngelli H, Gürbüz M, Arayici ME. Importance of hematological and inflammatory markers in the localization of gastric cancer. World J Gastrointest Oncol 2025; 17(4): 104455 [DOI: 10.4251/wjgo.v17.i4.104455]



World Journal of Gastrointestinal Oncology

Monthly Volume 17 Number 4 April 15, 2025

Retrospective Study

Potievskiy MB, Petrov LO, Ivanov SA, Sokolov PV, Trifanov VS, Grishin NA, Moshurov RI, Shegai PV, Kaprin AD. Machine learning for modeling and identifying risk factors of pancreatic fistula. World J Gastrointest Oncol 2025; 17(4): 100089 [DOI: 10.4251/wjgo.v17.i4.100089]

Lu JL, Cheng Y, Xu ZL, Qian GX, Wei MT, Jia WD. Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(4): 101371 [DOI: 10.4251/wjgo.v17.i4.101371]

Wang SY, Dong XT, Yuan Z, Jin LX, Gao WF, Han YK, Ni KM, Liu ZC, Wang JY, Wei XM, Su XM, Peng X, Zhang CZ. Factors associated with false fecal immunochemical test results in colorectal cancer screening. World J Gastrointest Oncol 2025; 17(4): 101487 [DOI: 10.4251/wjgo.v17.i4.101487]

Fei J, Qi LW, Liu Y, Shu M, Mo WQ. Comparing transarterial chemoembolization alone to combined transarterial chemoembolization and radiofrequency ablation in primary hepatocellular carcinoma treatment. World J Gastrointest Oncol 2025; 17(4): 102038 [DOI: 10.4251/wjgo.v17.i4.102038]

Mo YK, Chen XP, Hong LL, Hu YR, Lin DY, Xie LC, Dai ZZ. Gastric schwannoma: Computed tomography and perigastric lymph node characteristics. World J Gastrointest Oncol 2025; 17(4): 102085 [DOI: 10.4251/wjgo.v17.i4. 102085

Zhang Y, Zhu WL, Wu M, Gao TY, Hu HX, Xu ZY. Using bioinformatics methods to elucidate fatty acid-binding protein 4 as a potential biomarker for colon adenocarcinoma. World J Gastrointest Oncol 2025; 17(4): 103113 [DOI: 10. 4251/wjgo.v17.i4.103113]

Guo S, Liu FF, Yuan L, Ma WQ, Er LM, Zhao Q. Subclassification scheme for adenocarcinomas of the esophagogastric junction and prognostic analysis based on clinicopathological features. World J Gastrointest Oncol 2025; 17(4): 103455 [DOI: 10.4251/wjgo.v17.i4.103455]

Rong Y, Liu Y, Tang SY, Ju XJ, Li H. Caregiver-involved nutritional support and mindfulness training for patients with gastrointestinal cancer: Effects on malnutrition risk and mood. World J Gastrointest Oncol 2025; 17(4): 103515 [DOI: 10.4251/wjgo.v17.i4.103515]

Liang LW, Luo RH, Huang ZL, Tang LN. Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(4): 103631 [DOI: 10.4251/wjgo. v17.i4.103631]

Yu J, Liu QC, Lu SY, Wang S, Zhang H. Detecting plasma SHOX2, HOXA9, SEPTIN9, and RASSF1A methylation and circulating cancer cells for cholangiocarcinoma clinical diagnosis and monitoring. World J Gastrointest Oncol 2025; 17(4): 104253 [DOI: 10.4251/wjgo.v17.i4.104253]

Clinical Trials Study

Liu Y, Liu HG, Zhao C. Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer. World J Gastrointest Oncol 2025; 17(4): 103131 [DOI: 10.4251/wjgo.v17.i4. 103131

Sun MH, Shen HZ, Jin HB, Yang JF, Zhang XF. Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial. World J Gastrointest Oncol 2025; 17(4): 103311 [DOI: 10.4251/wjgo.v17.i4.103311]

Zhang SH, Li W, Chen XY, Nie LL. Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients. World [Gastrointest Oncol 2025; 17(4): 103855 [DOI: 10.4251/wjgo.v17.i4.103855]



World Journal of Gastrointestinal Oncology

Monthly Volume 17 Number 4 April 15, 2025

Observational Study

Suzuki M, Sakurazawa N, Hagiwara N, Kogo H, Haruna T, Ohashi R, Yoshida H. Usefulness of shear-wave elastography for detection of lymph node metastasis in esophageal and gastric cancer. World J Gastrointest Oncol 2025; 17(4): 101925 [DOI: 10.4251/wjgo.v17.i4.101925]

Prospective Study

Kekez D, Prejac J, Adžić G, Librenjak N, Goršić I, Jonjić D, Krznarić Ž, Augustin G, Pleština S. Phase angle as a prognostic biomarker in metastatic colorectal cancer: A prospective trial. World J Gastrointest Oncol 2025; 17(4): 103029 [DOI: 10.4251/wjgo.v17.i4.103029]

Wu XL, Li XS, Cheng JH, Deng LX, Hu ZH, Qi J, Lei HK. Oesophageal cancer-specific mortality risk and public health insurance: Prospective cohort study from China. World J Gastrointest Oncol 2025; 17(4): 103629 [DOI: 10.4251/ wjgo.v17.i4.103629

Basic Study

Lv XL, Peng QL, Wang XP, Fu ZC, Cao JP, Wang J, Wang LL, Jiao Y. Snail family transcriptional repressor 1 radiosensitizes esophageal cancer via epithelial-mesenchymal transition signaling: From bioinformatics to integrated study. World J Gastrointest Oncol 2025; 17(4): 97644 [DOI: 10.4251/wjgo.v17.i4.97644]

Tian HP, Xiao ZX, Su BW, Li YX, Peng H, Meng CY. Impact of SLC16A8 on tumor microenvironment and angiogenesis in colorectal cancer: New therapeutic target insights. World J Gastrointest Oncol 2025; 17(4): 99188 [DOI: 10.4251/wjgo.v17.i4.99188]

Shantha Kumara HMC, Addison P, Yan XH, Sharma AR, Mitra N, Angammana HN, Hedjar Y, Chen YR, Cekic V, Richard WL. Plasma extracellular cold inducible RNA-binding protein levels are elevated for 1 month postcolectomy which may promote metastases. World J Gastrointest Oncol 2025; 17(4): 100678 [DOI: 10.4251/wjgo.v17.i4. 100678

Ji PX, Zhang P, Zhou HL, Yu H, Fu Y. MEX3A promotes cell proliferation by regulating the RORA/β-catenin pathway in hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(4): 102084 [DOI: 10.4251/wjgo.v17.i4. 102084

Xin MJ, Yuan Y. Centromere protein A knockdown inhibits rectal cancer through O6-methylguanine DNA methyltransferase/protein tyrosine phosphatase nonreceptor type 4 axis. World J Gastrointest Oncol 2025; 17(4): 102619 [DOI: 10.4251/wjgo.v17.i4.102619]

Lu XF, Zhang HW, Chang X, Guo YZ. F-box protein 22: A prognostic biomarker for colon cancer associated with immune infiltration and chemotherapy resistance. World J Gastrointest Oncol 2025; 17(4): 102913 [DOI: 10.4251/ wjgo.v17.i4.102913

Meng FD, Jia SM, Ma YB, Du YH, Liu WJ, Yang Y, Yuan L, Nan Y. Identification of key hub genes associated with anti-gastric cancer effects of lotus plumule based on machine learning algorithms. World J Gastrointest Oncol 2025; 17(4): 103048 [DOI: 10.4251/wjgo.v17.i4.103048]

Ma FC, Zhang GL, Chi BT, Tang YL, Peng W, Liu AQ, Chen G, Gao JB, Wei DM, Ge LY. Blood-based machine learning classifiers for early diagnosis of gastric cancer via multiple miRNAs. World J Gastrointest Oncol 2025; 17(4): 103679 [DOI: 10.4251/wjgo.v17.i4.103679]

Xiao ZW, Zeng YC, Ji LT, Yuan JT, Li L. Nitric oxide synthase 1 inhibits the progression of esophageal cancer through interacting with nitric oxide synthase 1 adaptor protein. World J Gastrointest Oncol 2025; 17(4): 103843 [DOI: 10.4251/wjgo.v17.i4.103843]



World Journal of Gastrointestinal Oncology

Monthly Volume 17 Number 4 April 15, 2025

Hou YX, Ren W, He QQ, Huang LY, Gao TH, Li H. Tetramethylpyrazine induces reactive oxygen species-based mitochondria-mediated apoptosis in colon cancer cells. World J Gastrointest Oncol 2025; 17(4): 104922 [DOI: 10.4251/ wjgo.v17.i4.104922]

SCIENTOMETRICS

Zhang YR, Zhu HR, Li HR, Cheng YL, Yang SH, Sun SL, Wang Z. Trends in nanomedicine for colorectal cancer treatment: Bibliometric and visualization analysis (2010-2024). World J Gastrointest Oncol 2025; 17(4): 102438 [DOI: 10.4251/wjgo.v17.i4.102438]

CASE REPORT

Yi AQ, Xie GH. Pancreatic neuroendocrine neoplasms coexisting with biliary intraductal papillary mucinous neoplasm: A case report and review of literature. World J Gastrointest Oncol 2025; 17(4): 100497 [DOI: 10.4251/wjgo. v17.i4.100497

Tang XW, Zhou Y. Signet ring cell carcinoma of the appendix and terminal ileum: A case report. World J Gastrointest Oncol 2025; 17(4): 100526 [DOI: 10.4251/wjgo.v17.i4.100526]

Tachibana S, Moriichi K, Takahashi K, Sato M, Kobayashi Y, Sugiyama Y, Sasaki T, Sakatani A, Ando K, Ueno N, Kashima S, Tanabe H, Fujiya M. Curative endoscopic submucosal dissection for esophageal squamous cell carcinoma after chemoradiotherapy for pharyngeal cancer: A case report. World J Gastrointest Oncol 2025; 17(4): 101123 [DOI: 10.4251/wjgo.v17.i4.101123]

Li XL, Li M, Yang H, Tian J, Shi ZW, Wang LZ, Song K. Chronic myelogenous leukemia secondary to colon cancer: A case report. World J Gastrointest Oncol 2025; 17(4): 102021 [DOI: 10.4251/wjgo.v17.i4.102021]

Du XY, Xia RJ, Shen LW, Ma JG, Yao WQ, Xu W, Lin ZP, Ma LB, Niu GQ, Fan RF, Xu SM, Yan L. Quadruple therapy with immunotherapy and chemotherapy as first-line conversion treatment for unresectable advanced gastric adenocarcinoma: A case report. World J Gastrointest Oncol 2025; 17(4): 102258 [DOI: 10.4251/wjgo.v17.i4. 102258

Xiao X, Wang QW, Zhou ZY, Wang LS, Huang P. Precision treatment for human epidermal growth factor receptor 2-amplified advanced rectal cancer: A case report. World J Gastrointest Oncol 2025; 17(4): 102690 [DOI: 10.4251/ wjgo.v17.i4.102690

Zhang XY, Li C, Lin J, Zhou Y, Shi RZ, Wang ZY, Jiang HB, Wang YY. Intestinal obstruction caused by early stage primary ileum adenocarcinoma: A case report and review of literature. World J Gastrointest Oncol 2025; 17(4): 104919 [DOI: 10.4251/wjgo.v17.i4.104919]

LETTER TO THE EDITOR

Rojas A, González I, Morales MA. Natural products and cancer: The urgent need to bridge the gap between preclinical and clinical research. World J Gastrointest Oncol 2025; 17(4): 100484 [DOI: 10.4251/wjgo.v17.i4.100484]

Miao YR, Yang XJ. Hepatocellular carcinoma resistance to tyrosine kinase inhibitors: Current status and perspectives. World J Gastrointest Oncol 2025; 17(4): 101528 [DOI: 10.4251/wjgo.v17.i4.101528]

Krishnan A. Radiomics and machine learning for predicting metachronous liver metastasis in rectal cancer. World] Gastrointest Oncol 2025; 17(4): 102324 [DOI: 10.4251/wjgo.v17.i4.102324]

Sundararaju U, Rajakumar HK. Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer: Enhancing clinical relevance. World J Gastrointest Oncol 2025; 17(4): 103128 [DOI: 10.4251/wjgo.v17.i4.103128]



World Journal of Gastrointestinal Oncology

Monthly Volume 17 Number 4 April 15, 2025

Jeong KY. How is single-cell RNA sequencing contributing to the advancement of cancer therapeutics? World J Gastrointest Oncol 2025; 17(4): 103480 [DOI: 10.4251/wjgo.v17.i4.103480]

D'Acapito F, Framarini M, Di Pietrantonio D, Ercolani G. Personalized treatment selection in colorectal cancer with peritoneal metastasis: Do we need statistically validated indicators or cultural shift? World J Gastrointest Oncol 2025; 17(4): 104110 [DOI: 10.4251/wjgo.v17.i4.104110]



Monthly Volume 17 Number 4 April 15, 2025

ABOUT COVER

Peer Review of World Journal of Gastrointestinal Oncology, Jihwan Ko, MD, FRSPH, Director, Baekyang Jeil Internal Medicine Clinic, Busan 47181, South Korea. jihwanko65@gmail.com

AIMS AND SCOPE

The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for WJGO as 2.5; JIF without journal self cites: 2.5; 5-year JIF: 2.8; JIF Rank: 72/143 in gastroenterology and hepatology; JIF Quartile: Q3; and 5-year JIF Quartile: Q2. The WJGO's CiteScore for 2023 is 4.2 and Scopus CiteScore rank 2023: Gastroenterology is 80/167; Oncology is 196/404.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Si Zhao; Production Department Director: Xiang Li; Cover Editor: Jia-Ru Fan.

| NAME OF JOURNAL World Journal of Gastrointestinal Oncology | INSTRUCTIONS TO AUTHORS https://www.wjgnet.com/bpg/gerinfo/204 | | |
|---|---|--|--|
| ISSN | GUIDELINES FOR ETHICS DOCUMENTS | | |
| ISSN 1948-5204 (online) | https://www.wjgnet.com/bpg/GerInfo/287 | | |
| LAUNCH DATE | GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH | | |
| February 15, 2009 | https://www.wjgnet.com/bpg/gerinfo/240 | | |
| FREQUENCY | PUBLICATION ETHICS | | |
| Monthly | https://www.wjgnet.com/bpg/GerInfo/288 | | |
| EDITORS-IN-CHIEF | PUBLICATION MISCONDUCT | | |
| Monjur Ahmed | https://www.wjgnet.com/bpg/gerinfo/208 | | |
| EDITORIAL BOARD MEMBERS | ARTICLE PROCESSING CHARGE | | |
| https://www.wjgnet.com/1948-5204/editorialboard.htm | https://www.wjgnet.com/bpg/gerinfo/242 | | |
| PUBLICATION DATE | STEPS FOR SUBMITTING MANUSCRIPTS | | |
| April 15, 2025 | https://www.wjgnet.com/bpg/GerInfo/239 | | |
| COPYRIGHT | ONLINE SUBMISSION | | |
| © 2025 Baishideng Publishing Group Inc | https://www.f6publishing.com | | |

© 2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: office@baishideng.com https://www.wjgnet.com



XI

0 $W \hat{U}$

World Journal of **Gastrointestinal** Oncology

Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Oncol 2025 April 15; 17(4): 102084

DOI: 10.4251/wjgo.v17.i4.102084

ISSN 1948-5204 (online)

ORIGINAL ARTICLE

Basic Study MEX3A promotes cell proliferation by regulating the RORA/β-catenin pathway in hepatocellular carcinoma

Peng-Xiang Ji, Ping Zhang, Hui-Ling Zhou, Hong Yu, Yi Fu

Specialty type: Oncology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade A, Grade A, Grade C Novelty: Grade A, Grade A, Grade в

Creativity or Innovation: Grade A, Grade B, Grade B Scientific Significance: Grade A, Grade B, Grade C

P-Reviewer: Li ZM: Wei XE

Received: October 10, 2024 Revised: January 27, 2025 Accepted: February 14, 2025 Published online: April 15, 2025 Processing time: 166 Days and 13.5 Hours



Peng-Xiang Ji, Ping Zhang, Hand Surgery Laboratory, Suzhou Ruihua Orthopedic Hospital, Suzhou Medical College of Soochow University, Suzhou 215104, Jiangsu Province, China

Hui-Ling Zhou, Hong Yu, Department of Pathology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou 225300, Jiangsu Province, China

Yi Fu, Department of Human Anatomy, Histology and Embryology, Suzhou Medical College of Soochow University, Suzhou 215123, Jiangsu Province, China

Corresponding author: Yi Fu, PhD, Associate Professor, Department of Human Anatomy, Histology and Embryology, Suzhou Medical College of Soochow University, No. 199 Renai Road, Suzhou 215123, Jiangsu Province, China. yfu@suda.edu.cn

Abstract

BACKGROUND

MEX3A is a member of the human homologous gene MEX-3 family. It has been shown to promote cell proliferation and migration in various cancers, indicating its potential clinical significance. However, the role of MEX3A in hepatocellular carcinoma (HCC) remains largely unexplored, with limited reports available in the literature.

AIM

To investigate expression and clinical significance of MEX3A in HCC and explore its potential role in tumor progression.

METHODS

We analyzed MEX3A mRNA expression in HCC and adjacent tissues using data from The Cancer Genome Atlas (TCGA). The correlation between MEX3A expression and overall survival (OS) was evaluated. Immunohistochemistry was performed on HCC surgical specimens to validate MEX3A expression and its association with clinical parameters, including hepatitis B virus (HBV) positivity, tumor differentiation and tumor size. Additionally, MEX3A knockdown HCC cell lines were constructed to explore the biological functions of MEX3A. Cell proliferation was assessed using cell counting kit-8 and clone formation assays, while cell cycle progression was analyzed by flow cytometry. The effects of MEX3A on the Wnt/β-catenin signaling pathway were examined by western blotting and immunofluorescence. Cell migration was evaluated using scratch and Transwell



assays. Finally, the role of the transcription factor RORA in mediating MEX3A effects was explored by silencing RORA and analyzing its impact on cell proliferation and protein expression.

RESULTS

TCGA data analysis revealed that MEX3A mRNA expression was significantly higher in HCC tissues compared to adjacent tissues. Higher MEX3A expression was associated with poorer OS. These findings were validated in HCC surgical specimens. Immunohistochemistry confirmed elevated MEX3A expression in HCC tissues and showed positive correlations with Ki-67 and vimentin levels. MEX3A expression was closely related to HBV positivity, tumor differentiation and tumor size. Mechanistic studies demonstrated that MEX3A knockdown inhibited cell proliferation and cell cycle progression, as shown by reduced expression of β -catenin, c-Myc and cyclin D1. Additionally, MEX3A knockdown inhibited the nuclear entry of β -catenin, thereby suppressing the activation of downstream oncogenic pathways. MEX3A depletion significantly reduced the migratory ability of HCC cells, likely through downregulation of the epithelial-mesenchymal transition pathway. Transcription factor analysis identified RORA as a potential mediator of MEX3A effects. Silencing RORA antagonized the effects of MEX3A on cell proliferation and the expression of β -catenin, c-Myc and cyclin D1.

CONCLUSION

MEX3A promotes cell proliferation in HCC by regulating the RORA/ β -catenin pathway. Our findings suggest that MEX3A could serve as a prognostic marker and therapeutic target for HCC.

Key Words: Hepatocellular carcinoma; MEX3A; Proliferation; Migration; Wnt/β-catenin; Epithelial-mesenchymal transition pathway; RORA

©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This study found that MEX3A was highly expressed in hepatocellular carcinoma (HCC) and associated with poor prognosis. Immunohistochemistry showed that MEX3A expression was positively correlated with Ki-67 and vimentin, and closely related to clinical parameters. Knockdown of MEX3A inhibited cell proliferation and cell cycle progression; attenuated expression of β -catenin, c-Myc and cyclin D1; inhibited nuclear entry of β -catenin; and downregulated epithelial-mesenchymal transition to inhibit cell migration. Transcription factor analysis found that RORA might mediate the effects of MEX3A. In conclusion, MEX3A may promote proliferation of HCC cells by regulating the RORA/ β -catenin pathway.

Citation: Ji PX, Zhang P, Zhou HL, Yu H, Fu Y. MEX3A promotes cell proliferation by regulating the RORA/β-catenin pathway in hepatocellular carcinoma. *World J Gastrointest Oncol* 2025; 17(4): 102084 **URL:** https://www.wjgnet.com/1948-5204/full/v17/i4/102084.htm **DOI:** https://dx.doi.org/10.4251/wjgo.v17.i4.102084

INTRODUCTION

Primary liver cancer is one of the most common malignant tumors and it ranks sixth in incidence and third in mortality among all malignancies[1]. Hepatocellular carcinoma (HCC) accounts for 75%-85% of all liver cancer cases[2]. Due to its insidious onset, insignificant early symptoms, easy metastasis and recurrence, the treatment efficacy of HCC is unsatisfactory. According to data from the National Cancer Institute, the incidence of liver cancer remained stable in males but continued to rise slowly in females during 2013 to 2019. The 5-year relative survival rate for liver cancer patients diagnosed during this period was approximately 22%[3]. Cancer treatment has made significant progress in recent years, with advances in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy. These treatments have improved patient outcomes and survival rates, but challenges remain, including the need for more personalized and effective therapies to address the complexity and heterogeneity of cancer[4]. Therefore, it is important to find effective prognostic markers and therapeutic targets to realize the early diagnosis and treatment of HCC.

MEX3A is a member of the human homologous gene MEX3 family (*MEX3A*, *MEX3B*, *MEX3C* and *MEX3D*), located on human chromosome 1q22. The MEX3A protein was first discovered in *Caenorhabditis elegans* (*C. elegans*) by Buchet-Poyau *et al*[5] and this protein acts as a translation regulator to inhibit the translation of plasminogen activator inhibitor-1 in the early embryos of *C. elegans*. With the in-depth study of this gene, it has been discovered that MEX3A is also closely related to the occurrence of many diseases, such as cancer. Expression of MEX3A in cancer tissues is significantly higher than that in adjacent tissues in bladder and ovarian cancers[6,7]. Jiang *et al*[8] found that knockdown of MEX3A gene expression inhibited the proliferation, migration and clone formation ability of gastric cancer cells.

These studies indicated that MEX3A functions as an oncogene, promoting cancer development. Hu *et al*[9] found 13 genes, including MEX3A, whose high expression was related to poor prognosis in HCC by using The Cancer Genome Atlas (TCGA) database-derived cohort transcriptome profiles. Ding *et al*[10] found that the MEX3A had a higher mutation

frequency in HCC patients, and its expression was often elevated in high-risk patients. However, the function and mechanism of MEX3A in HCC has not been well studied.

β-Catenin is a key component of the Wnt signaling pathway and plays crucial roles in various diseases other than cancer. In osteoporosis, studies have shown that icariin exerts anti osteoporotic effects in ovariectomized rats through the Wnt/ β -catenin pathway, highlighting its potential therapeutic application[11]. In pulmonary fibrosis, Wnt/ β -catenin signaling is implicated in the pathogenesis, with research indicating that a WNT mimetic can reduce fibrosis and improve lung function in bleomycin-induced models [12]. β -Catenin plays a crucial role in HCC. It can promote the proliferation, migration and invasion of HCC cells by activating the Wnt/β-catenin signaling pathway. For example, mutations in the CTNNB1 gene encoding β -catenin can increase glutamine production, which affects tumor epigenetics and other related pathways, thereby driving HCC progression [13]. Additionally, the expression of β -catenin in HCC tissues is negatively correlated with the degree of pathological differentiation, and its high expression indicates poor prognosis. Research has shown that the average survival time of patients with positive β -catenin expression is significantly shorter than that of those with negative expression [14,15]. In this study, we confirmed high expression of MEX3A in HCC tissues and preliminarily explored the function and molecular mechanism of MEX3A in the proliferation and migration of HCC. We found that the RORA/β-catenin signaling pathway and epithelial-mesenchymal transition (EMT) pathway were implicated in MEX3A-mediated cell growth and migration.

MATERIALS AND METHODS

Patients and tissue samples

In our study, 26 patients with histologically confirmed HCC tissues were obtained from Taizhou People's Hospital. Tumor and adjacent nontumor tissues were collected. All specimens were obtained at the time of surgery, then analyzed immunohistochemically. Our study was approved by the Ethics Committee of Taizhou People's Hospital (KY2019040). We confirmed that all patients provided informed consent.

Data acquisition and expression analysis

RNA sequencing data and the corresponding clinical data of HCC patients were downloaded from the TCGA database (http://cancergenome.nih.gov/), which contained information of 369 HCC tissues and 52 adjacent nontumor liver tissues. MEX3A expression data from the tumor and adjacent nontumor tissues were analyzed using the ggstatsplot package of R software (version 3.4.1).

Kaplan-Meier analysis

Kaplan-Meier analysis was performed to evaluate the association between MEX3A expression levels and overall survival (OS) in HCC patients. Patients were stratified into two groups based on high and low MEX3A expression levels. The criteria for stratification were determined by the median expression level of MEX3A in HCC tissues. Specifically, the high-expression group included patients with MEX3A expression levels above the median (n = 170), while the lowexpression group included those with MEX3A expression levels below the median (n = 171). The analysis was performed using R software with the survival package. The hazard ratios and 95% confidence intervals were calculated to quantify the risk of death associated with high MEX3A expression levels.

Functional enrichment analysis

HCC tissues were divided into MEX3A-high and MEX3A-low expression groups (top and bottom 10% of MEX3A expression levels) and differentially expressed genes were analyzed with the R package edge R[16]. Using the hallmark gene set in the MSigDB database^[17] as the reference gene set, GSEA analysis was performed by the R package cluster Profiler[18] and plotted using the R package enrich plot[19].

Transcription factor analysis

Samples were divided into high/low expression groups (10%) according to MEX3A expression, and differential gene expression analysis was performed by the R package edge R[16], and the sets of differentially expressed genes that were up- and downregulated (in the same way as the previous one) were obtained. Transcription factor analysis was performed by the R package RcisTarget[20], and tabulation was performed by using the R package DT (https://CRAN.Rproject.org/package=DT).

Correlation analysis between cell differentiation markers and expression of MEX3A

Spearman correlations between the expression of RORA, c-Myc, SRY-Box Transcription Factor 9 (SOX9) and MEX3A of HCC tissues were analyzed and visualized by the R package ggpubr (https://CRAN.R-project.org/package=ggpubr).

Plasmid construction

The PLKO.1 (#10879) plasmid purchased from add gene was linearized by Age I (Thermo Scientific, MA, United States) and EcoRI (Thermo). The two synthesized shRNAs (shMEX3A-1: CCGGAGGCAAGGCTGCAAGATTAAGCTCGAGCT-TAATCTTGCAGCCTTGCCTTTTTTG; shMEX3A-2: CCGGCACGCAAGCCATCCGAATATTCTCGAGAATATTCGGAT-GGCTTGCGTGTTTTTG) were annealed and inserted into the linearized vector by T4 DNA ligase (Thermo Scientific). After successful sequencing, they were used for subsequent transfection experiments. The siRNA of RORA (5'-



GCUUGUAUGCAGAAGUACA-3') was synthesized by Tsingke Biotechnology (Beijing, China).

Cell culture and passaging

Human hepatoma cell lines HepG2 and MHCC-97H were donated from Minghua Wang's group at Soochow University. Both cell lines were cultured in Dulbecco's modified Eagle' smedium (Hyclone, Utah, United States) containing 10% fetal bovine serum (BI, Israel) and 1% penicillin-streptomycin (Thermo Scientific) in a humidified incubator at 37°C and 5% CO₂, and passages were performed every 2 days.

Cell transfection and stable strain construction

HCC cells (2×10^5) were inoculated into six-well plates, transfected 12-24 hours after inoculation; 2 µg plasmid and Lipofectamine 3000 Transfection Reagent (Invitrogen, CA, United States) were premixed into six-well plates, and the medium was changed after 6 hours. After 24 hours of transfection, the cells were subjected to selection with $2 \mu g/mL$ puromycin for 72 hours, the concentration was reduced to 1 µg/mL for long-term culture. After four to five generations of screening, the stable strain was constructed and used for subsequent experiments.

Cell counting kit-8 assay

The constructed negative control and knockdown cell lines were digested with trypsin and diluted into a cell suspension. A cell counting plate was used to count the cell number, and 10³ cells were inoculated in each well of a 96-well plate. Four duplicate wells were set in each experimental group and the control group, and seeded into the 96-well to allow the cells to adhere. Cell counting kit-8 (CCK-8) (NCM biotech, Jiangsu, China) was put back into the cell incubator for 2 hours incubation, and absorbance at 450 nm wavelength was detected by a microplate reader (Thermo Scientific). Subsequently, the 96-well plates were taken out every 24 hours for repeat detection. The cell growth curve was drawn with the cell culture time as the horizontal axis and OD 450 as the vertical axis.

Cell clone formation assay

The constructed stable strain was digested to a cell suspension, and diluted to a final concentration of 500 cells/mL. The cell suspension was inoculated into a 12-well plate at 1 mL per well. Three replicates were set up for the experimental and control groups. The plates were shaken gently to disperse the cells evenly and placed in a 37 °C, 5% CO₂ incubator for static culture. Medium was replaced every 3-4 days, and the plates were cultured continuously for 2 weeks. The plates were washed, fixed and stained with 0.1% crystalline violet solution. The formed clones were observed and counted with Image J. GraphPad was performed for statistical analysis.

Cell cycle analysis

Cells were treated with serum-free medium for 24 hours to achieve synchronization, and serum-containing medium was then added for 48 hours. Cells were digested, washed and fixed overnight at -20 °C, then stained with propidium iodide at 37 °C for 30 minutes, and RNase was added to remove RNA at the same time. Finally, flow cytometry was performed for cell cycle detection.

Cell scratch assay

The cells were seeded into a six-well plate to reach 90% confluence. Artificial gaps were created by scraping with a 200 mL pipette tip. The wound area was photographed with a phase contrast microscope at 0 and 24 hours post-scratch. The images were analyzed by Image J software 1.35 and mobility was calculated.

Transwell migration assay

The cells of the experimental and control groups were digested and resuspended in serum-free medium. The cell concentration was adjusted to 5 \times 10⁵ cells /mL. The Transwell chamber was placed in a 24-well plate, and 600 μ L medium containing20% serum was added to the lower chamber. Uniformly mixed cell suspension (200 µL) was taken and added dropwise into the upper chamber, and cultured for 24 hours. The chamber was taken out, fixed and stained. Five randomly selected fields of view were observed under the microscope and photographs were taken.

Real-time fluorescent quantitative PCR

The reverse transcription system was prepared according to the instructions of the Novizinkit (Vazyme, Jiangsu, China). The reaction product cDNA was placed on ice for subsequent operations or stored at -80 °C. Real-time fluorescent quantitative PCR (RT-qPCR) was used to detect the mRNA levels of genes in cells. ACTB was used as an internal reference, and the quantitative primers used were all designed by NCBI (https://www.ncbi.nlm.nih.gov/). The primer sequences are shown in Supplementary Table 1.

Western blotting

The cells were harvested and the protein was extracted. The protein concentration was corrected by the BCA protein quantification kit (Beyotime, Shanghai, China). Equal amounts of protein (30 mg) were loaded on each lane and separated by SDS/PAGE, followed by transfer to PVDF membranes. The membranes (Millipore, MA, United States) were blocked in 5% skimmed milk and incubated with primary antibody overnight at 4 °C. The antibodies againstMEX3A, c-Myc, β catenin, cyclin D1, E-cadherin, N-cadherin, p21, RORA, β-actin and GAPDH were all obtained from Abcam (London, United Kingdom). After washing with TBST, the membranes were incubated with secondary antibody for 90 minutes at



37 °C. Finally, bands were visualized with an ECL and imaged by Tanon imaging system.

Immunohistochemical staining

Tissue sections (4 mm) were heated at 60 °C for 30 minutes and treated with 3% H_2O_2 at 25 °C for 10 minutes. Slides were soaked in distilled water for 10 minutes, blocked with10% BSA at 25 °C for 30 minutes, and incubated with the primary antibody MEX3A (1: 400 dilution) overnight. Tissue sections were rinsed twice for 5 minutes with phosphate-buffered saline (PBS). These sections were incubated for 1 hour at 25 °C and diaminobenzidine was added. The sections were stained with hematoxylin for 30 sto stain the nuclei. According to the intensity of staining and the percentage of positively stained cells, expression of MEX3A protein was divided into low and high. After determining expression of MEX3A, immunohistochemical staining was repeated for Ki-67 (with a 1:500 dilution) and vimentin (with a 1:200 dilution) in the low and high MEX3A expression groups. The antibodies against Ki-67 and vimentin were all obtained from Abcam.

Immunofluorescence

The cells were washed with PBS. The tissue was fixed with 4% (v/v) paraformaldehyde for 15 minutes, and 0.2% Triton X-100 was used to permeabilize the tissue for 20 minutes. The cells were blocked with 10% goat serum (v/v) for 1 hour. Subsequently, tissues were incubated with primary antibodies at 37 °C for 2 hand exposed to secondary antibody (1: 50; Bio world Technology) at 20 °C for 2 hours. Nuclear counterstaining was then performed using 4',6-diamidino-2-phenylindole (Beyotime) for 5 minutes. The stained samples were imaged under a fluorescence microscope (Carl Zeiss AG, Oberkochen, Germany).

Statistical analysis

At least three independent experiments were performed for each experiment, and each experiment was set up with at least three replicates. The mean \pm SD was used as the measurement data. Image J software was used for cell counting, GraphPad prism 8 software was used for statistical analysis, and *t*-test was used to compare the means between different groups. *P* < 0.05 was considered to be statistically significant.

RESULTS

MEX3A expression analysis

The TCGA (https://cancergenome.nih.gov/) database was used to query MEX3A mRNA expression. Expression of MEX3A in HCC tissues was significantly higher than that in normal tissues (Figure 1A). Expression of MEX3A was significantly associated with age (Figure 1B) and clinical stage, which was increased in Stages I-IV (Figure 1C). Kaplan-Meier analysis revealed that patients with high expression of MEX3A exhibited a shorter OS than those with low expression. These results suggest that elevated MEX3A expression is a potential prognostic marker for poor outcomes in HCC (Figure 1D).

MEX3A expression in clinical specimens

RT-qPCR was performed on 26 surgical specimens of HCC. Expression of MEX3A mRNA in cancer tissues was higher than that in adjacent noncancerous tissues (Figure 2A), which was consistent with the results from the TCGA database. Hematoxylin and eosin staining demonstrated that HCC tissues consisted of tumor cells that resembled hepatocytes. Tumor cells showed marked variation in cellular and nuclear size, shape and staining (Figure 2B). Immunohistochemical staining was used to measure expression of MEX3A protein in tissues. Among the 26 pairs of HCC and adjacent nontumor tissues, MEX3A was positively expressed in all HCC tissues, while negatively expressed in adjacent normal tissues. The cell proliferation marker Ki-67 is expressed in the nucleus, whereas mesenchymal marker vimentin is predominatly expressed in the intercellular substance. Their levels in cancer tissues were higher than those in adjacent tissues (Figure 2C). The number of MEX3A protein expression in the HCC tissues was 65.4% (17/26), and the weak positive rate was 34.6% (9/26) (Table 1). We further selected representative samples with high and low expression of MEX3A for Ki-67 and vimentin staining. Expression of Ki-67 and vimentin was consistent with that of MEX3A (Figure 3). This result suggests that the increase of MEX3A promotes proliferation and metastasis of HCC, and MEX3A could be used as a biomarker for diagnosis of HCC.

Relationship between MEX3A expression and clinical parameters

The relationship between MEX3A expression and clinical features of 26 cases of HCC was statistically analyzed. High expression of MEX3A was correlated with the tumor diameter (P = 0.0085), differentiation (P = 0.0277) and hepatitis B virus (HBV) positivity (P = 0.0461), but there was no significant association between MEX3A expression and gender, age, tumor-node-metastasis stage, serum a-fetoprotein level, liver cirrhosis and vascular invasion (Table 1). Studies have found that SOX9 and c-Myc contribute to the stemness characteristics in HCC[21,22]. Spearman correlations analysis found a significant positive correlation between expression of MEX3A and HCC differentiation factors SOX9 and c-Myc (Supplementary Figure 1), suggesting that MEX3A correlates with HCC differentiation. In conclusion, MEX3A may be a potential prognostic biomarker for HCC.



| Table 1 Correlation between MEX3A expression and clinical parameters in hepatocellular carcinoma | | | | | | | |
|--|------------------|---------------|---------|-----------|---------------------|--|--|
| Parameters | MEX3A expression | | | | | | |
| | | <i>n</i> = 26 | Low (9) | High (17) | <i>P</i> value | | |
| Gender | Male | 24 | 8 | 16 | 1 | | |
| | Female | 2 | 1 | 1 | | | |
| Age (year) | < 65 | 14 | 5 | 9 | 1 | | |
| | 65 | 12 | 4 | 8 | | | |
| TNM stage | T1, T2 | 7 | 1 | 6 | 0.3574 | | |
| | T3, T4 | 19 | 8 | 11 | | | |
| HBV | + | 16 | 3 | 13 | 0.0461 ^a | | |
| | - | 10 | 6 | 4 | | | |
| AFP (ng/mL) | < 400 | 19 | 6 | 13 | 0.6613 | | |
| | 400 | 7 | 3 | 4 | | | |
| Tumor diameter | < 5 | 10 | 7 | 3 | 0.0085 ^a | | |
| | 5 | 16 | 2 | 14 | | | |
| Differentiation | High | 9 | 6 | 3 | 0.0277 ^a | | |
| | Low | 17 | 3 | 14 | | | |
| Hepatocirrhosis | + | 16 | 5 | 11 | 0.6924 | | |
| | - | 10 | 4 | 6 | | | |
| Vascular invasion | + | 21 | 7 | 14 | 1 | | |
| | - | 5 | 2 | 3 | | | |

 $^{a}P < 0.05.$

AFP: A-fetoprotein; TNM: Tumor node metastasis; HBV: Hepatitis B virus.

MEX3A silencing inhibits cell proliferation in HCC

To explore the biological function of MEX3A in HCC, we designed two MEX3A shRNA sequences and constructed the stable transfected strains in HCC cell lines HepG2 and MHCC-97H, which were denoted as shMEX3A-1 and shMEX3A-2, respectively. The control group was denoted as shNC. Western blotting showed that both shRNA sequences downreg-ulated expression of MEX3A (Figure 4A and B). We explored the effect of knockdown of MEX3A on cell proliferation in HepG2 and MHCC-97H cells. Using the previously constructed control group (shNC) and MEX3A knockdown group (shMEX3A-1, shMEX3A-2) cell lines, CCK-8 assay was used to detect cell growth. The proliferation of HepG2 and MHCC-97H cells was significantly inhibited after MEX3A knockdown, especially at days 3 and 4 (Figure 4C and D). Since the inhibitory role of shMEX3A-1 on HCC cell proliferation was more pronounced, we selected it for the subsequent study. The effect of MEX3A on clone formation was examined and showed that MEX3A silencing significantly inhibited clone formation compared with the control group (Figure 4E and F). These results indicated that MEX3A could promote cell proliferation in HCC cells and might play an important role in the occurrence and development of HCC.

MEX3A silencing induces cell cycle arrest through Wnt/β-catenin in HCC

We explored the role of MEX3A in the cell cycle. Flow cytometry showed that inhibition of MEX3A expression resulted in an increase in G1 phase cells and a decrease percentage in S phase HepG2 cells (Figure 5A and B) and MHCC-97H cells (Figure 5C and D), which indicated that knockdown of MEX3A inhibited cell proliferation, resulting in cell cycle G1 phase arrest. The Wnt/ β -catenin signaling pathway plays crucial roles in HCC progression, including proliferation and migration[23] and c-Myc and cyclin D1 are targets of the Wnt/ β -catenin pathway[24]. P21 is a broad-spectrum cell cycledependent kinase inhibitor and a negative regulator of the cell cycle with the ability to prevent cells from passing through the G1/S phase[25]. Therefore, we examined the effect of MEX3A silencing on these proteins. Knockdown of MEX3A decreased expression of β -catenin, c-Myc and cyclin D1 but increased expression of p21 (Figure 5E and F). We evaluated the localization of β -catenin in the cells by immunofluorescence. The results indicated that knockdown of MEX3A leads to decreased expression of β -catenin in the nucleus, which meant that the activity of Wnt/ β -catenin pathway was inhibited (Figure 5G). These results suggested that MEX3A promoted HCC proliferation through enhancing the activity of Wnt/ β catenin signaling pathway.

Zaisbideng® WJGO https://www.wjgnet.com



Figure 1 Analysis of MEX3A expression. A: Differential expression of MEX3A mRNA in hepatocellular carcinoma (HCC) and adjacent non-tumor tissues (P < 0.001); B and C: Differential expression of MEX3A mRNA in HCC according to age (P = 0.013) and tumor-node-metastasis stages (P < 0.001); D: Kaplan-Meier survival analysis of MEX3A in HCC (P < 0.001).

MEX3A silencing attenuates cell migration through the EMT pathway in HCC

Gene set enrichment analysis (GSEA) found that MEX3A has important effects on genes that were mainly related to oxidative phosphorylation, G2/M checkpoint, EMT and the JAK/STAT pathway (Figure 6A). Also, some evidence has shown that MEX3A promotes the invasion and metastasis of pancreatic ductal adenocarcinoma by affecting expression of EMT-related proteins, such as N-cadherin[26]. Further GSEA revealed that high expression of MEX3A was enriched in the EMT pathway in HCC (Figure 6B), indicating that MEX3A influenced the cell migration of HCC through the EMT pathway. We explored the effect of MEX3A on the migration of HCC by cell scratch and Transwell experiments. Compared with the shNC groups, the shMEX3A groups of the two cell lines showed low migration (Figure 6C-F), indicating that knockdown of MEX3A impairs the migratory ability of HCC cells. The expression of E-cadherin was increased and N-cadherin was decreased by MEX3A silencing (Figure 5E and F), further supporting that MEX3A may facilitate cell migration through the EMT pathway in HCC.

MEX3A silencing upregulates expression of RORA

Through transcription factor analysis, we found there was a motif of transcription factor RORA in the promoter region of differential genes related to expression of MEX3A (Figure 7A), suggesting that RORA might regulate expression of differential genes at transcriptional level. To verify the correlation between MEX3A and RORA, we conducted correlation analysis and found that MEX3A and RORA were negatively correlated (Figure 7B). The upstream and downstream relationship between differential genes and MEX3A is not clear, and RORA may be upstream or downstream of MEX3A. We synthesized siRNA to inhibit expression of RORA and found that knockdown of MEX3A upregulated expression of RORA in HepG2 cells, while knockdown of RORA had no significant effect on MEX3A expression (Figure 7C and D), which suggests that RORA is a downstream gene of MEX3A.

Zaishideng® WJGO | https://www.wjgnet.com



Figure 2 MEX3A expression in clinical specimens. A: Real-time fluorescent quantitative PCR was used to detect expression of MEX3A mRNA in hepatocellular carcinoma (HCC) and adjacent tissues; B: Hematoxylin and eosin staining in HCC and adjacent tissues; C: Expression of MEX3A, Ki-67 and vimentin in HCC and adjacent tissues was detected by immunohistochemistry. Scale bar = 100 and 50 µm.

RORA antagonizes the effect of MEX3A on cell proliferation

It has been reported that RORA plays a tumor-inhibitory role in several cancers by attenuating the Wnt/β-catenin pathway[27-29]. To test whether MEX3A stimulates cell growth in HCC through RORA/β-catenin, we transfected RORA siRNA in shMEX3A-HepG2 cell line to construct a double knockdown cell model. RT-qPCR and western blotting showed that expression of RORA obviously increased in shMEX3A group, while apparently decreased in double knockdown group (Figure 8A-C), which proved again that RORA is downstream of MEX3A. Next, we investigated the impact of three different genetic knockdown strategies on cell proliferation in HepG2 cells. Specifically, we compared the effects of the shMEX3A group, the RORA siRNA group, and the MEX3A/RORA double knockdown group. CCK-8 assay and clone formation showed that MEX3A knockdown inhibited cell growth, which is consistent with the previous results. Compared with the MEX3A knockdown group, cell growth was increased in the MEX3A/RORA double knockdown group (Figure 8D-F), indicating that interference of RORA could compensate for the proliferation inhibition in HepG2 cells induced by knockdown of MEX3A. Western blotting was used to examine the effect of RORA on protein levels in the Wnt/ β -catenin pathway. Downregulation of β -catenin expression caused by MEX3A knockdown was partially reversed in the double knockdown group. Similar results were found for c-Myc and cyclin D1 (Figure 8G and H). Additionally, the immunofluorescence experiments revealed that silencing RORA can counteract the inhibitory effect of MEX3A knockdown on β-catenin nuclear translocation (Figure 8I). These data suggested that RORA was at least partially involved in the activation of the Wnt/ β -catenin pathway induced by MEX3A. However, knockdown of RORA had little effect on expression of E-cadherin and N-cadherin (Figure 8G and H), suggesting that MEX3A regulates the EMT

Zaishideng® WJGO https://www.wjgnet.com



Figure 3 Low and high expression of MEX3A, Ki-67 and vimentin in hepatocellular carcinoma tissues. Scale bar = 100 and 50 µm.

pathway not through RORA, but by an alternative mechanism.

DISCUSSION

In this study, the TCGA data were collected and subjected to bioinformatics analysis. The results showed that there was a very significant upregulation of MEX3A mRNA expression in HCC compared with adjacent tissues, and the expression of this gene was closely related to the age, clinical stage and the poor prognosis of liver cancer, which agrees with the report of Yang et al[30]. The TCGA database has been widely used in cancer research, encompassing studies on single genes in individual cancers^[31], gene sets in individual cancers^[32], single genes across multiple cancers (pan-cancer)^[33], and gene sets across multiple cancers (pan-cancer)[34]. Although the TCGA database offers a wealth of resources for cancer research, it also has some potential biases. The generation and analysis of TCGA data may have technical limitations, and gene expression is complex and multifaceted. These factors need to be considered carefully[35].

Our initial bioinformatics analysis of TCGA data revealed significant insights into the role of MEX3A in HCC, highlighting its potential as a biomarker and therapeutic target. Building on these findings, we proceeded to validate these observations through experimental studies using clinical HCC specimens. This approach allowed us to confirm the bioinformatic predictions and delve deeper into the clinical significance of MEX3A expression in HCC.

Subsequently, 26 pairs of HCC specimens were used to verify the MEX3A expression and relationship between MEX3A and clinical features. The results showed that MEX3A was positively expressed in all HCC tissues, while negatively expressed in adjacent tissues. Ki-67 and vimentin was also detected and the result showed that both were highly expressed in samples with high expression of MEX3A, which hinted that MEX3A might play roles in cell proliferation and migration in HCC. The high expression of MEX3A was associated with tumor diameter and differentiation, indicating that MEX3A plays an important role in the development of HCC. We also found that the expression of MEX3A was correlated with the infection status of HBV, suggesting that MEX3A plays a key role in HBV-related HCC. However, the current study was limited by its small sample size. Future research with larger cohorts is needed to validate the relationship between MEX3A and HBV infection, as well as the specific mechanisms by which MEX3A contributes to the development and progression of HCC. Nevertheless, there was no relationship between MEX3A expression and age or clinical stage. Although the MEX3A mRNA in the TCGA database showed a significant difference with age, the difference in MEX3A mRNA was small. Our immunohistochemistry results indicated that MEX3A protein expression was not affected by age. It is hypothesized that the minor difference in mRNA level may not lead to a significant change in protein expression. In addition, the lack of association with age might have been related to our elatively small sample size. It is reported that SOX9 and c-Myc can act as differentiation markers because of their ability to sustain the stemness characteristics of HCC[36], and we found that expression of MEX3A was positively related to the expression of SOX9 and c-Myc by bioinformatics analysis. Our western blotting results showed that knockdown of MEX3A could decreased expression of c-Myc, which suggests that MEX3A expression is correlated with differentiation of HCC, indicating that MEX3A is a potential prognostic biomarker for HCC. Our CCK-8 assay and clone formation experiment showed that downregulation



Raishidena® WJGO https://www.wjgnet.com



Figure 4 Effect of MEX3A on cell proliferation in hepatocellular carcinoma. A and B: Western blotting detection of knockdown efficiency of MEX3A in HepG2 and MHCC-97H cell lines; C and D: Cell counting kit-8 assay was used to detect the effect of knockdown of MEX3A on proliferation of HepG2 and MHCC-97H cells; E and F: Crystal violet staining was used to detect the clone formation ability of the two cell lines. Data are presented as the mean \pm SD. ^aP < 0.05, ^bP < 0.01, ^oP < 0.001.

 Zaishideng®
 WJGO
 https://www.wjgnet.com



Baishideng® WJGO

WJGO https://www.wjgnet.com

April 15, 2025 Volume 17 Issue 4



Figure 5 Effects of MEX3A on cell cycle and related protein expression. A and B: Flow cytometry was used to examine the effect of knockdown of MEX3A on the cell cycle in HepG2 cells; C and D: Flow cytometry was used to examine the effect of knockdown of MEX3A on the cell cycle in MHCC-97H cells. Data are presented as the mean ± SD; E and F: Western blotting detection of the effect of MEX3A silencing on levels of proteins in the Wnt/b-catenin and epithelialmesenchymal transition pathways; G: Immunofluorescence detection of the effect of MEX3A silencing on localization of β-catenin. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. Scale bar = 50 µm.

of MEX3A inhibited growth of HepG2 and MHCC-97H cell lines. Also, knockdown of MEX3A induced cell cycle G1 phase arrest by increasing the number in G1 phase and decreasing the number in S phase, which verifies the proliferative effect of MEX3A on HCC. Cyclins are a family of proteins that play important roles in regulating the cell cycle. Cyclin D1 drives G1/S phase transition[37]. P21 is a cell cycle inhibitor that can prevent cell cycle progression at G1 phase[38]. Fei et al[39] reported that cyclin D1 and p21 participated in G0/G1 cell cycle arrest in HepG2 cells. We found that MEX3A silencing decreased expression of cyclin D1 and increased the level of p21, which blocked the G1/S transition. There is accumulating evidence that the Wnt/ β -catenin signaling pathway plays critical roles in progression of HCC[40]. C-Myc and cyclin D1 are downstream molecules of the Wnt/β-catenin pathway[24,41,42]. C-Myc is a well-studied protooncogene, and its abnormal expression can lead to 30%-50% of human malignant tumors[43]. Our results showed that knockdown of MEX3A decreased the nuclear translocation of β-catenin, and inhibited expression of c-Myc and cyclin D1. These data demonstrated that MEX3A could promote cell proliferation by activating the Wnt/β-catenin pathway.

HCC progresses rapidly, and its invasiveness is closely linked to its migratory and invasive capabilities. EMT induces cancer cell metastasis and invasion, playing a key role in migration of HCC[44]. E-cadherin, N-cadherin and vimentin are involved in EMT and they are important indicators of this pathway. During EMT, the expression of E-cadherin gradually



Zaishideng® WJGO https://www.wjgnet.com





Caishideng® WJGO | https://www.wjgnet.com



Figure 6 Effect of MEX3A on cell migration in hepatocellular carcinoma. A: Gene set enrichment analysis (GSEA) of MEX3A expression and key pathways; red color represents statistically significant results. The size of the circle represents the number of genes; B: GSEA of MEX3A expression and epithelial-mesenchymal transition pathway; C and D: Cell scratch assay was used to detect the effect of MEX3A on cell migration; E and F: Transwell assay was used to detect the effect of MEX3A on hepatocellular carcinoma migration. Data are presented as the mean \pm SD. ^aP < 0.01, ^bP < 0.001. Scale bar in C-F = 100 µm.



Figure 7 RORA can be regarded as a downstream gene for MEX3A. A: Analysis of transcription factors found a binding motif for the transcription factor RORA at the promoter of the differential genes associated with MEX3A expression; B: Correlation between RORA and MEX3A; C and D: QPCR was used to detect mRNA level of RORA and MEX3A after knockdown of MEX3A and RORA. Data are presented as the mean ± SD. ^aP < 0.001.

decreased, while the expression of N-cadherin and vimentin increased[45]. GSEA found that high expression of MEX3A in HCC was closely related to the EMT pathway. The cell scratch and Transwell assays showed that downregulation of MEX3A inhibited migration of HCC. Immunohistochemistry showed that vimentin was highly expressed in HCC tissues. Western blotting found that expression of E-cadherin was upregulated and expression of N-cadherin was downregulated after MEX3A knockdown, indicating that MEX3A could promote HCC migration through the EMT pathway. The EMT pathway plays a complex and diverse role in cancer metastasis, particularly in HCC. Some studies have shown that signaling pathways within the EMT pathway, such as PI3K/PDK1/AKT and Ras-GTP/Raf/MEK/ERK/MAPK, are activated through interactions with various receptor tyrosine kinases of growth factors, leading to expression of EMT factors such as Twist and Snail Homolog 1/2. The ERK/MAPK pathway requires the combination with other signaling pathways, such as Notch, Wnt, and NF- κ B, to more effectively induce EMT[46]. Although we have found that MEX3A affects gene expression changes related to EMT, validation of these findings can be considered in future studies using patient-derived xenograft models, which can simulate the heterogeneity and complexity of human cancers, thereby better understanding the metastatic mechanisms of HCC and developing more effective treatment methods[47].

GSEA obtained differential genes from MEX3A high expression and low expression groups. Transcription factor analysis found that a RORA motif in the promoter region of differential genes. Although MEX3A was weakly correlated with RORA, Lee *et al*[29] have reported that RORA can act as a transcription factor to regulate the Wnt/ β -catenin

Zaishideng® WJGO | https://www.wjgnet.com





Saishideng® WJGO https://www.wjgnet.com



Figure 8 Role of RORA in hepatocellular carcinoma as a downstream gene for MEX3A. A-C: Real-time fluorescent quantitative PCR and western blotting detection of the knockdown efficiency of MEX3A and RORA; D: Cell counting kit-8 assay detection of the proliferative ability of the cells divided into four groups of HepG2 cells ("c"represents significant difference between the shNC + siNC and shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significant difference between the shMEX3A + siNC groups; "d" represents significan

pathway. Therefore, we wanted to observe whether MEX3A can regulate cell proliferation as well as the Wnt/ β -catenin pathway through RORA. We found that RORA was located downstream of MEX3A and reversed the cell proliferation induced by MEX3A. Western blotting also revealed that RORA could partly antagonize the effects of MEX3A on the expression of β -catenin, c-Myc and cyclin D1, which suggested that RORA participated in regulation of MEX3A on the Wnt/ β -catenin signaling pathway.

In conclusion, MEX3A is highly expressed and plays important roles in HCC, and promotes cell proliferation through the RORA/ β -catenin signaling pathway. However, how MEX3A exerts its regulatory effect on RORA is still unknown. Since MEX3A is an RNA-binding protein, it may regulate the expression of RORA at the post-transcriptional level, which will be the subject of our next study. MEX3A can regulate the migration of HCC cells through the EMT pathway, but is not associated with RORA (Figure 9).

Baishidena® WJGO | https://www.wjgnet.com



Figure 9 Schematic representation of mechanisms by which MEX3A promotes hepatocellular carcinoma cell proliferation and migration. HCC: Hepatocellular carcinoma.

CONCLUSION

Our study demonstrates that MEX3A promotes cell proliferation in HCC by regulating the RORA/β-catenin pathway, highlighting its potential as a prognostic marker and therapeutic target.

ACKNOWLEDGEMENTS

We would like to thank all the patients who generously participated in this study.

FOOTNOTES

Author contributions: Fu Y experiment design and manuscript writing; Ji PX experiment performing, data analysis, and manuscript writing; Zhang P experiment performing; Zhou HL and Yu H clinical samples collecting and data analysis.

Supported by Suzhou Municipal Science and Technology Bureau, No. SYS2020081.

Institutional review board statement: Our study was approved by Ethics Committee of the Affiliated Taizhou People's Hospital (KY2019040).

Institutional animal care and use committee statement: Our study does not involve animal experiments.

Informed consent statement: We have applied to the Ethics Committee for a waiver of informed consent signatures and have received approval. At the same time, we have provided all patients with written information about the study to ensure they fully understand the content and purpose of the research.

Conflict-of-interest statement: The authors declared that they have no conflict of interest to this work.

Data sharing statement: No data associated with this study needs to be deposited into a publicly available repository. The analysis presented in this study utilized publicly available databases through bioinformatics tools. All relevant results and findings from the bioinformatics analysis are comprehensively detailed within the manuscript and the accompanying Supplementary materials. Therefore, no additional data need to be deposited.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: China



WJGO https://www.wjgnet.com

ORCID number: Peng-Xiang Ji 0000-0001-9455-1564; Yi Fu 0000-0002-3820-8996.

S-Editor: Qu XL L-Editor: A P-Editor: Zhang XD

REFERENCES

- 1 Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int 2022; 42: 2029-2041 [PMID: 35319165 DOI: 10.1111/liv.15251]
- 2 Ma C, Zhang Q, Greten TF. MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target. Cell Immunol 2021; **361**: 104295 [PMID: 33508529 DOI: 10.1016/j.cellimm.2021.104295]
- . Erratum to "Cancer statistics, 2024". CA Cancer J Clin 2024; 74: 203 [PMID: 38363123 DOI: 10.3322/caac.21830] 3
- Sonkin D, Thomas A, Teicher BA. Cancer treatments: Past, present, and future. Cancer Genet 2024; 286-287: 18-24 [PMID: 38909530 DOI: 4 10.1016/j.cancergen.2024.06.002]
- 5 Buchet-Poyau K, Courchet J, Le Hir H, Séraphin B, Scoazec JY, Duret L, Domon-Dell C, Freund JN, Billaud M. Identification and characterization of human Mex-3 proteins, a novel family of evolutionarily conserved RNA-binding proteins differentially localized to processing bodies. Nucleic Acids Res 2007; 35: 1289-1300 [PMID: 17267406 DOI: 10.1093/nar/gkm016]
- Huang Y, Fang C, Shi JW, Wen Y, Liu D. Identification of hMex-3A and its effect on human bladder cancer cell proliferation. Oncotarget 6 2017; 8: 61215-61225 [PMID: 28977858 DOI: 10.18632/oncotarget.18050]
- Li F, Zhao C, Diao Y, Wang Z, Peng J, Yang N, Qiu C, Kong B, Li Y. MEX3A promotes the malignant progression of ovarian cancer by 7 regulating intron retention in TIMELESS. Cell Death Dis 2022; 13: 553 [PMID: 35715407 DOI: 10.1038/s41419-022-05000-7]
- Jiang H, Zhang X, Luo J, Dong C, Xue J, Wei W, Chen J, Zhou J, Gao Y, Yang C. Knockdown of hMex-3A by small RNA interference 8 suppresses cell proliferation and migration in human gastric cancer cells. Mol Med Rep 2012; 6: 575-580 [PMID: 22692246 DOI: 10.3892/mmr.2012.943]
- Hu B, Yang XB, Sang XT. Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for 9 Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020; 7: 315-330 [PMID: 33204664 DOI: 10.2147/JHC.S272109]
- 10 Ding J, He X, Luo W, Zhou W, Chen R, Cao G, Chen B, Xiong M. Development and Validation of a Pyroptosis-Related Signature for Predicting Prognosis in Hepatocellular Carcinoma. Front Genet 2022; 13: 801419 [PMID: 35140750 DOI: 10.3389/fgene.2022.801419]
- Chen G, Wang C, Wang J, Yin S, Gao H, Xiang LU, Liu H, Xiong Y, Wang P, Zhu X, Yang LI, Zhang R. Antiosteoporotic effect of icariin in 11 ovariectomized rats is mediated via the Wnt/β-catenin pathway. Exp Ther Med 2016; 12: 279-287 [PMID: 27347050 DOI: 10.3892/etm.2016.3333
- Patel M, Post Y, Hill N, Sura A, Ye J, Fisher T, Suen N, Zhang M, Cheng L, Pribluda A, Chen H, Yeh WC, Li Y, Baribault H, Fletcher RB. A 12 WNT mimetic with broad spectrum FZD-specificity decreases fibrosis and improves function in a pulmonary damage model. Respir Res 2024; 25: 153 [PMID: 38566174 DOI: 10.1186/s12931-024-02786-2]
- Ziki RA, Colnot S. Glutamine metabolism, a double agent combating or fuelling hepatocellular carcinoma. JHEP Rep 2024; 6: 101077 [PMID: 13 38699532 DOI: 10.1016/j.jhepr.2024.101077]
- Liu L, Zhu XD, Wang WQ, Shen Y, Qin Y, Ren ZG, Sun HC, Tang ZY. Activation of beta-catenin by hypoxia in hepatocellular carcinoma 14 contributes to enhanced metastatic potential and poor prognosis. Clin Cancer Res 2010; 16: 2740-2750 [PMID: 20460486 DOI: 10.1158/1078-0432.CCR-09-2610
- Zhao Z, Cui T, Wei F, Zhou Z, Sun Y, Gao C, Xu X, Zhang H. Wnt/β-Catenin signaling pathway in hepatocellular carcinoma: pathogenic role 15 and therapeutic target. Front Oncol 2024; 14: 1367364 [PMID: 38634048 DOI: 10.3389/fonc.2024.1367364]
- Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. 16 Bioinformatics 2010; 26: 139-140 [PMID: 19910308 DOI: 10.1093/bioinformatics/btp616]
- Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set 17 collection. Cell Syst 2015; 1: 417-425 [PMID: 26771021 DOI: 10.1016/j.cels.2015.12.004]
- Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012; 16: 284-18 287 [PMID: 22455463 DOI: 10.1089/omi.2011.0118]
- Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, Fu X, Liu S, Bo X, Yu G. clusterProfiler 4.0: A universal 19 enrichment tool for interpreting omics data. Innovation (Camb) 2021; 2: 100141 [PMID: 34557778 DOI: 10.1016/j.xinn.2021.100141]
- Van de Sande B, Flerin C, Davie K, De Waegeneer M, Hulselmans G, Aibar S, Seurinck R, Saelens W, Cannoodt R, Rouchon Q, Verbeiren T, 20 De Maeyer D, Reumers J, Saeys Y, Aerts S. A scalable SCENIC workflow for single-cell gene regulatory network analysis. Nat Protoc 2020; 15: 2247-2276 [PMID: 32561888 DOI: 10.1038/s41596-020-0336-2]
- Kawai T, Yasuchika K, Ishii T, Miyauchi Y, Kojima H, Yamaoka R, Katayama H, Yoshitoshi EY, Ogiso S, Kita S, Yasuda K, Fukumitsu K, 21 Komori J, Hatano E, Kawaguchi Y, Uemoto S. SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma. Sci Rep 2016; 6: 30489 [PMID: 27457505 DOI: 10.1038/srep30489]
- Holczbauer Á, Factor VM, Andersen JB, Marquardt JU, Kleiner DE, Raggi C, Kitade M, Seo D, Akita H, Durkin ME, Thorgeirsson SS. 22 Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology 2013; 145: 221-231 [PMID: 23523670 DOI: 10.1053/j.gastro.2013.03.013]
- Deldar Abad Paskeh M, Mirzaei S, Ashrafizadeh M, Zarrabi A, Sethi G. Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma 23 Progression: An Emphasis on Molecular Pathways. J Hepatocell Carcinoma 2021; 8: 1415-1444 [PMID: 34858888 DOI: 10.2147/JHC.S336858]
- Lecarpentier Y, Schussler O, Hébert JL, Vallée A. Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers. Front Oncol 24 2019; 9: 1248 [PMID: 31803621 DOI: 10.3389/fonc.2019.01248]
- Spencer SL, Cappell SD, Tsai FC, Overton KW, Wang CL, Meyer T. The proliferation-quiescence decision is controlled by a bifurcation in 25 CDK2 activity at mitotic exit. Cell 2013; 155: 369-383 [PMID: 24075009 DOI: 10.1016/j.cell.2013.08.062]



- Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY. The E-Cadherin and N-Cadherin Switch in Epithelial-26 to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells 2019; 8 [PMID: 31547193 DOI: 10.3390/cells8101118]
- Sun X, Dongol S, Qiu C, Xu Y, Sun C, Zhang Z, Yang X, Zhang Q, Kong B. miR-652 Promotes Tumor Proliferation and Metastasis by 27 Targeting RORA in Endometrial Cancer. Mol Cancer Res 2018; 16: 1927-1939 [PMID: 30093563 DOI: 10.1158/1541-7786.MCR-18-0267]
- Huang JL, Fu YP, Gan W, Liu G, Zhou PY, Zhou C, Sun BY, Guan RY, Zhou J, Fan J, Yi Y, Qiu SJ. Hepatic stellate cells promote the 28 progression of hepatocellular carcinoma through microRNA-1246-RORα-Wnt/β-Catenin axis. Cancer Lett 2020; 476: 140-151 [PMID: 32061951 DOI: 10.1016/j.canlet.2020.02.012]
- 29 Lee JM, Kim IS, Kim H, Lee JS, Kim K, Yim HY, Jeong J, Kim JH, Kim JY, Lee H, Seo SB, Kim H, Rosenfeld MG, Kim KI, Baek SH. RORalpha attenuates Wnt/beta-catenin signaling by PKCalpha-dependent phosphorylation in colon cancer. Mol Cell 2010; 37: 183-195 [PMID: 20122401 DOI: 10.1016/j.molcel.2009.12.022]
- 30 Yang D, Jiao Y, Li Y, Fang X. Clinical characteristics and prognostic value of MEX3A mRNA in liver cancer. PeerJ 2020; 8: e8252 [PMID: 31998552 DOI: 10.7717/peerj.8252]
- Liu H, Weng J, Huang CL, Jackson AP. Is the voltage-gated sodium channel β 3 subunit (SCN3B) a biomarker for glioma? Funct Integr 31 Genomics 2024; 24: 162 [PMID: 39289188 DOI: 10.1007/s10142-024-01443-7]
- 32 Liu H, Tang T. A bioinformatic study of IGFBPs in glioma regarding their diagnostic, prognostic, and therapeutic prediction value. Am J Transl Res 2023; 15: 2140-2155 [PMID: 37056850]
- 33 Liu H, Dilger JP, Lin J. A pan-cancer-bioinformatic-based literature review of TRPM7 in cancers. Pharmacol Ther 2022; 240: 108302 [PMID: 36332746 DOI: 10.1016/j.pharmthera.2022.108302]
- Liu H, Tang T. Pan-cancer genetic analysis of cuproptosis and copper metabolism-related gene set. Front Oncol 2022; 12: 952290 [PMID: 34 36276096 DOI: 10.3389/fonc.2022.952290]
- Liu H, Guo Z, Wang P. Genetic expression in cancer research: Challenges and complexity. Gene Rep 2024; 37: 102042 [DOI: 35 10.1016/j.genrep.2024.102042]
- Buchynska LG, Brieieva OV, Iurchenko NP. Assessment of HER-2/neu, c-MYC and CCNE1 gene copy number variations and protein 36 expression in endometrial carcinomas. Exp Oncol 2019; 41: 138-143 [PMID: 31262163 DOI: 10.32471/exp-oncology.2312-8852.vol-41-no-2.12973]
- Park MS, Koff A. Overview of the cell cycle. Curr Protoc Cell Biol 2001; Chapter 8: Unit 8.1 [PMID: 18228386 DOI: 37 10.1002/0471143030.cb0801s00]
- Huang GL, Zhang W, Ren HY, Zhou P, Chen Y, Chen QX, Shen DY. Oncogenic retinoic acid receptor a promotes human colorectal cancer 38 growth through simultaneously regulating p21 transcription and GSK3β/β-catenin signaling. Cancer Lett 2017; 388: 118-129 [PMID: 27932034 DOI: 10.1016/j.canlet.2016.11.038]
- Fei HR, Chen HL, Xiao T, Chen G, Wang FZ. Caudatin induces cell cycle arrest and caspase-dependent apoptosis in HepG2 cell. Mol Biol Rep 39 2012; **39**: 131-138 [PMID: 21553057 DOI: 10.1007/s11033-011-0721-6]
- Leung RWH, Lee TKW. Wnt/β-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma. 40 Cancers (Basel) 2022; 14 [PMID: 36358885 DOI: 10.3390/cancers14215468]
- He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of 41 the APC pathway. Science 1998; 281: 1509-1512 [PMID: 9727977 DOI: 10.1126/science.281.5382.1509]
- Jia XX, Zhu TT, Huang Y, Zeng XX, Zhang H, Zhang WX. Wnt/β-catenin signaling pathway regulates asthma airway remodeling by 42 influencing the expression of c-Myc and cyclin D1 via the p38 MAPK-dependent pathway. Exp Ther Med 2019; 18: 3431-3438 [PMID: 31602218 DOI: 10.3892/etm.2019.7991]
- Zheng K, Cubero FJ, Nevzorova YA. c-MYC-Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease. Genes 43 (Basel) 2017; 8 [PMID: 28422055 DOI: 10.3390/genes8040123]
- Xu X, Zhang Y, Wang X, Li S, Tang L. Substrate Stiffness Drives Epithelial to Mesenchymal Transition and Proliferation through the NEAT1-44 Wnt/β-Catenin Pathway in Liver Cancer. Int J Mol Sci 2021; 22 [PMID: 34769497 DOI: 10.3390/ijms222112066]
- Kaszak I, Witkowska-Piłaszewicz O, Niewiadomska Z, Dworecka-Kaszak B, Ngosa Toka F, Jurka P. Role of Cadherins in Cancer-A Review. 45 Int J Mol Sci 2020; 21 [PMID: 33076339 DOI: 10.3390/ijms21207624]
- Liaghat M, Ferdousmakan S, Mortazavi SH, Yahyazadeh S, Irani A, Banihashemi S, Seyedi Asl FS, Akbari A, Farzam F, Aziziyan F, 46 Bakhtiyari M, Arghavani MJ, Zalpoor H, Nabi-Afjadi M. The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors. Cell Commun Signal 2024; 22: 575 [PMID: 39623377 DOI: 10.1186/s12964-024-01957-4]
- 47 Li R, Huang Y, Liu H, Dilger JP, Lin J. Abstract 2162: Comparing volatile and intravenous anesthetics in a mouse model of breast cancer metastasis. Cancer Res 2018; 78: 2162-2162 [DOI: 10.1158/1538-7445.am2018-2162]



WJGO | https://www.wjgnet.com



Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

